Abstract
Corrigendum to “The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004–2017” [Eur J Canc 145 (2021) 11–18
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have